000273975 001__ 273975
000273975 005__ 20250127091352.0
000273975 0247_ $$2pmc$$apmc:PMC11649178
000273975 0247_ $$2doi$$a10.1212/NXI.0000000000200343
000273975 0247_ $$2pmid$$apmid:39671210
000273975 037__ $$aDZNE-2024-01424
000273975 041__ $$aEnglish
000273975 082__ $$a610
000273975 1001_ $$00000-0001-5226-6650$$aHeine, Josephine$$b0
000273975 245__ $$aPatient-Reported Outcome Measures in NMDA Receptor Encephalitis.
000273975 260__ $$aPhiladelphia, Pa.$$bWolters Kluwer$$c2025
000273975 3367_ $$2DRIVER$$aarticle
000273975 3367_ $$2DataCite$$aOutput Types/Journal article
000273975 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1736936102_13620
000273975 3367_ $$2BibTeX$$aARTICLE
000273975 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000273975 3367_ $$00$$2EndNote$$aJournal Article
000273975 520__ $$aThe characteristics of persistent long-term symptoms and their contribution to subjective quality of life remain unclear in patients with NMDAR encephalitis. In this study, we aimed to evaluate postacute neuropsychiatric symptoms, subjective cognitive complaints, and disease coping mechanisms and identify predictors of health-related quality of life (HRQoL) after N-methyl-D-aspartate receptor (NMDAR) encephalitis.This cross-sectional observational study investigated patients with NMDAR encephalitis in the postacute phase. Psychometric scales included assessment of neuropsychiatric symptoms (i.e., fatigue, sleep, anxiety, and depressive symptoms), HRQoL, everyday independence, metamemory (i.e., self-rated ability, satisfaction, and use of strategies), and coping strategies (i.e., self-efficacy, disease-related coping, and stress management).A total of 50 patients (mean age 26.0 ± 10.1 years, 86% female) participated at a median of 4.15 (range 0.3-30.3) years after symptom onset. Patients reported significantly increased levels of anxiety (Beck Anxiety Inventory: 10.5 ± 7.7 [mean ± SD], 95% CI [8.32-12.71], p < 0.001) and depressive (Beck Depression Inventory-II: 11.4 ± 7.7 [9.22-13.62], p = 0.001) symptoms compared with the normative population. Both sleep problems (Pittsburgh Sleep Quality Index: 5.8 ± 3.0 [4.98-6.66], p < 0.001) and motor and cognitive fatigue (Fatigue Scale for Motor and Cognitive Function: 50.5 ± 23.1 [42.5-58.4], p < 0.001) were significantly more prevalent. Moreover, lower self-rated memory ability (Multifactorial Memory Questionnaire score: 54.6 ± 8.5 [52.1-57.1], p = 0.004) was associated with greater reliance on compensatory strategies and memory aids (r = -0.41, p = 0.004). Patients used significantly fewer cognitive coping strategies, such as relativization (11.7 ± 4.7 [10.3-13.1], p = 0.001), while depressive coping prevailed (49.1 ± 15.5 [44.5-53.8], p < 0.001). It is important to note that HRQoL was predicted by self-reported affective symptoms, self-efficacy, and coping behaviors in multivariable regression analyses, but not by acute disease severity or postacute physical disability.Our findings show that persistent neuropsychiatric and subjective cognitive concerns explain a large part of the reduced quality of life in patients with NMDAR encephalitis. These findings have important implications for a patient-centered postacute care and the role of disease coping strategies in the neurorehabilitation of autoimmune encephalitis.
000273975 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000273975 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000273975 650_2 $$2MeSH$$aHumans
000273975 650_2 $$2MeSH$$aFemale
000273975 650_2 $$2MeSH$$aMale
000273975 650_2 $$2MeSH$$aAnti-N-Methyl-D-Aspartate Receptor Encephalitis: complications
000273975 650_2 $$2MeSH$$aAnti-N-Methyl-D-Aspartate Receptor Encephalitis: psychology
000273975 650_2 $$2MeSH$$aAnti-N-Methyl-D-Aspartate Receptor Encephalitis: physiopathology
000273975 650_2 $$2MeSH$$aAdult
000273975 650_2 $$2MeSH$$aCross-Sectional Studies
000273975 650_2 $$2MeSH$$aPatient Reported Outcome Measures
000273975 650_2 $$2MeSH$$aQuality of Life
000273975 650_2 $$2MeSH$$aYoung Adult
000273975 650_2 $$2MeSH$$aAdaptation, Psychological: physiology
000273975 650_2 $$2MeSH$$aAdolescent
000273975 650_2 $$2MeSH$$aMiddle Aged
000273975 7001_ $$00000-0002-1727-3625$$aBoeken, Ole Jonas$$b1
000273975 7001_ $$00000-0002-6161-6621$$aRekers, Sophia$$b2
000273975 7001_ $$00000-0003-0952-5658$$aWurdack, Katharina$$b3
000273975 7001_ $$0P:(DE-2719)2810931$$aPrüss, Harald$$b4
000273975 7001_ $$0P:(DE-2719)9001141$$aFinke, Carsten$$b5
000273975 773__ $$0PERI:(DE-600)2767740-0$$a10.1212/NXI.0000000000200343$$gVol. 12, no. 1, p. e200343$$n1$$pe200343$$tNeurology: Neuroimmunology & Neuroinflammation ; official journal of the American Academy of Neurology$$v12$$x2332-7812$$y2025
000273975 8564_ $$uhttps://pub.dzne.de/record/273975/files/DZNE-2024-01424.pdf$$yOpenAccess
000273975 8564_ $$uhttps://pub.dzne.de/record/273975/files/DZNE-2024-01424.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000273975 909CO $$ooai:pub.dzne.de:273975$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000273975 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810931$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000273975 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000273975 9141_ $$y2025
000273975 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-29
000273975 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-29
000273975 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000273975 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROL-NEUROIMMUNOL : 2022$$d2023-08-29
000273975 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-13T18:57:06Z
000273975 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-13T18:57:06Z
000273975 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-29
000273975 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-29
000273975 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-29
000273975 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-29
000273975 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000273975 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-02-13T18:57:06Z
000273975 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-29
000273975 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROL-NEUROIMMUNOL : 2022$$d2023-08-29
000273975 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-29
000273975 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-29
000273975 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-29
000273975 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Encephalopathies$$x0
000273975 980__ $$ajournal
000273975 980__ $$aVDB
000273975 980__ $$aUNRESTRICTED
000273975 980__ $$aI:(DE-2719)1810003
000273975 9801_ $$aFullTexts